Akeso, Inc. (HKG:9926)
135.50
+7.80 (6.11%)
Sep 12, 2025, 4:08 PM HKT
Akeso Revenue
Akeso had revenue of 1.41B CNY in the half year ending June 30, 2025, a decrease of -61.61%. This brings the company's revenue in the last twelve months to 2.51B, up 33.97% year-over-year. In the year 2024, Akeso had annual revenue of 2.12B, down -53.08%.
Revenue (ttm)
2.51B CNY
Revenue Growth
+33.97%
P/S Ratio
45.37
Revenue / Employee
827.26K CNY
Employees
3,035
Market Cap
124.81B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
Dec 31, 2021 | 225.63M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
JD Health International | 71.34B |
Hansoh Pharmaceutical Group Company | 14.45B |
Innovent Biologics | 12.52B |
Sino Biopharmaceutical | 33.49B |
WuXi Biologics | 21.98B |
Alibaba Health Information Technology | 32.81B |
CSPC Pharmaceutical Group | 28.49B |
Akeso News
- 4 days ago - Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Benzinga
- 16 days ago - Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst - Benzinga
- 17 days ago - Akeso (9926.HK) Soars on Positive Lung Cancer Drug Trial Results - GuruFocus
- 17 days ago - Akeso shares surge as cancer drug achieves key milestone in China trial - Seeking Alpha
- 3 months ago - Chinese biotech firm Akeso sinks after US partner’s cancer-drug setback - South China Morning Post
- 4 months ago - Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
- 4 months ago - China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug - South China Morning Post
- 5 months ago - What's Going On With Summit Therapeutics Stock On Friday? - Benzinga